scholarly journals Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid

2018 ◽  
Vol 20 (1) ◽  
pp. 46-55 ◽  
Author(s):  
Tatsuo Hata ◽  
Marco Dal Molin ◽  
Anne McGregor-Das ◽  
Tae Jun Song ◽  
Christopher Wolfgang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Intraductal Papillary Mucinous Neoplasm ◽  
Pancreatic Cyst ◽  
Cyst Fluid ◽  
Mucinous Neoplasm ◽  
Simple Detection ◽  
Pancreatic Cyst Fluid

scholarly journals Micro-RNA Analysis of Pancreatic Cyst Fluid for Diagnosing Malignant Transformation of Intraductal Papillary Mucinous Neoplasm by Comparing Intraductal Papillary Mucinous Adenoma and Carcinoma

2021 ◽  
Vol 10 (11) ◽  
pp. 2249
Author(s):  
Yohei Shirakami ◽  
Takuji Iwashita ◽  
Shinya Uemura ◽  
Hisashi Imai ◽  
Katsutoshi Murase ◽  
...  
Keyword(s):  
Malignant Transformation ◽  
Intraductal Papillary Mucinous Neoplasm ◽  
Pancreatic Cyst ◽  
Cyst Fluid ◽  
Micro Rna ◽  
Diagnostic Methods ◽  
Cystic Fluid ◽  
Mucinous Neoplasm ◽  
Micro Rnas ◽  
Pancreatic Cyst Fluid

Although intraductal papillary mucinous neoplasm (IPMN) is thought to be a precursor lesion of pancreatic cancer, diagnosing malignant transformation of IPMN using non-invasive diagnostic methods is difficult and complicated. Micro-RNAs (miRNAs) are currently recognized as biomarkers and molecular targets of various diseases, including malignancy. In this study, we investigated a potential diagnostic approach using miRNA in pancreatic cyst fluid as a marker for evaluating malignant alternation of IPMN. Cystic fluid was sampled mainly during surgical resection. The collected samples were evaluated by performing comprehensive analysis of miRNA using a highly sensitive DNA chip. miRNA expression was compared between IPM adenoma (IPMA) and IPM carcinoma (IPMC) to evaluate the related biomarkers for malignant transformation of IPMN. miRNA analysis revealed that six miRNAs (miR-711, miR-3679-5p, miR-6126, miR-6780b-5p, miR-6798-5p, and miR-6879-5p) in IPMC were significantly enriched compared to those in IPMA. The difference was validated using quantitative real-time PCR. Cyst fluid miRNA analysis might be useful for diagnosing malignant alteration of IPMN. Further evaluations of diagnostic capability as well as functional analysis using the identified miRNAs are required with larger cohorts to confirm its efficacy.

scholarly journals Marker Identification of the Grade of Dysplasia of Intraductal Papillary Mucinous Neoplasm in Pancreatic Cyst Fluid by Quantitative Proteomic Profiling

Cancers ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2383
Author(s):  
Misol Do ◽  
Hongbeom Kim ◽  
Dongyoon Shin ◽  
Joonho Park ◽  
Haeryoung Kim ◽  
...  
Keyword(s):  
Intraductal Papillary Mucinous Neoplasm ◽  
Pancreatic Cyst ◽  
Laboratory Data ◽  
Cyst Fluid ◽  
Cystic Lesions ◽  
Proteomic Profiling ◽  
Cystic Fluid ◽  
Mucinous Neoplasm ◽  
Peptide Fractionation ◽  
Pancreatic Cyst Fluid

The incidence of patients with pancreatic cystic lesions, particularly intraductal papillary mucinous neoplasm (IPMN), is increasing. Current guidelines, which primarily consider radiological features and laboratory data, have had limited success in predicting malignant IPMN. The lack of a definitive diagnostic method has led to low-risk IPMN patients undergoing unnecessary surgeries. To address this issue, we discovered IPMN marker candidates by analyzing pancreatic cystic fluid by mass spectrometry. A total of 30 cyst fluid samples, comprising IPMN dysplasia and other cystic lesions, were evaluated. Mucus was removed by brief sonication, and the resulting supernatant was subjected to filter-aided sample preparation and high-pH peptide fractionation. Subsequently, the samples were analyzed by LC-MS/MS. Using several bioinformatics tools, such as gene ontology and ingenuity pathway analysis, we detailed IPMNs at the molecular level. Among the 5834 proteins identified in our dataset, 364 proteins were differentially expressed between IPMN dysplasia. The 19 final candidates consistently increased or decreased with greater IPMN malignancy. CD55 was validated in an independent cohort by ELISA, Western blot, and IHC, and the results were consistent with the MS data. In summary, we have determined the characteristics of pancreatic cyst fluid proteins and discovered potential biomarkers for IPMN dysplasia.

Targeted Proteomic Analysis of Pancreatic Cyst Fluid Accurately Identifies Cystic Precursors and Forms of Pancreatic Cancer

2017 ◽  
Vol 152 (5) ◽  
pp. S148-S149
Author(s):  
Karolina S. Jabbar ◽  
Liisa Arike ◽  
Caroline S. Verbeke ◽  
Riadh Sadik ◽  
Gunnar C. Hansson
Keyword(s):  
Pancreatic Cancer ◽  
Proteomic Analysis ◽  
Pancreatic Cyst ◽  
Cyst Fluid ◽  
Pancreatic Cyst Fluid

Exosomal miRNA signature of pancreatic cyst: Liquid biopsies as indicators of pancreatic cancer.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 225-225
Author(s):  
Virendra Joshi ◽  
Dominic Guanzon ◽  
Cris Molina ◽  
Zarin Nuzhat ◽  
Gregory Rice ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Small Rna ◽  
Pancreatic Cyst ◽  
Cyst Fluid ◽  
Pancreatic Cysts ◽  
Liquid Biopsies ◽  
Pancreatic Fluid ◽  
Mucinous Neoplasms ◽  
Exosomal Mirna ◽  
Pancreatic Cyst Fluid

225 Background: Pancreatic cysts are a group of lesions with malignant potential. Currently, there are no consistently reliable biomarkers or imaging modalities to accurately predict biologic behavior of these cysts. We tested the hypothesis that tumor-derived exosomes (better conserved than free miRNA) can be acquired endoscopically from pancreatic cyst fluid and may allow for improved distinction between benign, premalignant and malignant cysts. Methods: Exosomes were isolated and characterised by differential and buoyant centrifugation from pancreatic cyst fluid obtained from 30 patients with pseudocysts (PS), serous cystic (SC), mucinous cysts (MC), intraductal papillary mucinous neoplasms (IPMN), pancreatitis (PA), and pancreatic cancer (PC) , confirmed with imaging and histology. An Illumina TruSeq Small RNA kit was used to construct a small RNA library, and the libraries were sequenced using the Illumina NextSeq 500 platform. The resulting sequencing FASTQ files were analyzed using miRDeep2 to identify both known and novel miRNAs. Results: Four significant miRNAs which are shared between six of the analyses, specifically hsa-miR-199b-3p, hsa-miR-199a-2-3p, hsa-miR-199a-1-3p and hsa-let-7i-5p were identified. MiRNA hsa-miR-27a-3p was significant and shared between five of the analyses. A total of 15, 12 and 2 significant miRNAs were shared between four, three and two of the analyses, respectively. Importantly, there were a total of 10 significant miRNAs which were unique to each analysis, with the exception of IPMN vs Pseudocyst, and Pancreatic cancer vs Pancreatitis. Specifically these unique miRNAs for each analysis are: hsa-miR-92a-2-3p (Pancreatitis vs Pseudocyst); hsa-miR-92a-1-3p (Serous vs Pseudocyst); hsa-miR-30e-5p (Pancreatic cancer vs Serous), hsa-miR-30b-5p (IPMN vs Pancreatic cancer); and hsa-miR-23b-3p, hsa-miR-99b-5p, hsa-miR-222-3p, hsa-miR-31-5p, hsa-miR-151a-5p, hsa-miR-221-3p (Pancreatic cancer vs. Pseudocyst). Conclusions: Exosomal miRNAs in pancreatic fluid may be used as a biomarker to differentiate between various cyst types and pancreatic cancer. A larger cohort with miRNA quantification and is needed to further validate these findings .

Sign in / Sign up

Export Citation Format

Share Document